骨髄線維症における貧血のために利用可能なオプションを再評価します
Nipponese.news,
1738902293 2025-02-07 03:00:00 Andrew Kuykendall、MD（モデレーター） 悪性血液学部のアシスタントメンバー モフィットがんセンター タンパ、フロリダ ディスカッションの質問
JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis
OncLive,
Ashwin Kishtagari, MD In an interview with OncLive® following the Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium…
Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting
OncLive,
Gabriela Hobbs, MD Ruxolitinib (Jakafi)-based combinations continue to demonstrate promising ability to address splenomegaly…
Navitoclax Significantly Reduces Spleen Volume in Myelofibrosis
Oncology Nursing News,
Naveen Pemmaraju, MD For patients with myelofibrosis, the addition of navitoclax to ruxolitinib (Jakafi) was associated with a…